Methylphenidate
| 證據等級: L5 | 預測適應症: 4 個 |
目錄
Methylphenidate: From ADHD to Faciodigitogenital Syndrome
One-Sentence Summary
Methylphenidate is a central nervous system stimulant with long-established use in treating Attention Deficit Hyperactivity Disorder (ADHD) and narcolepsy, acting primarily through dopamine and norepinephrine reuptake inhibition. The TxGNN model predicts it may be effective for Faciodigitogenital Syndrome (Aarskog-Scott syndrome), however, no clinical trials and no publications currently support this specific direction — placing this at evidence level L5 (model prediction only).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | ADHD (Attention Deficit Hyperactivity Disorder) |
| Predicted New Indication | Faciodigitogenital Syndrome |
| TxGNN Prediction Score | 99.998% |
| Evidence Level | L5 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack. Based on known pharmacological information, Methylphenidate functions as a dopamine transporter (DAT) and norepinephrine transporter (NET) blocker, elevating synaptic catecholamine concentrations in the prefrontal cortex and striatum. This mechanism underpins its clinical efficacy in ADHD and attention-related disorders.
Faciodigitogenital syndrome (Aarskog-Scott syndrome) is a rare X-linked condition caused by mutations in the FGD1 gene, resulting in defective Rho GTPase / cytoskeletal signalling. The disease core involves impaired cell scaffolding and developmental morphogenesis — a pathway mechanistically unrelated to catecholamine reuptake inhibition. No known pharmacological bridge connects DAT/NET blockade to FGD1 protein function.
The high TxGNN score most likely reflects knowledge-graph topology: co-occurring phenotypic features such as cognitive developmental delay and behavioural difficulties create statistical proximity between Methylphenidate’s indication neighbourhood and this rare syndrome. This is considered a high-risk false-positive signal rather than a genuine mechanistic prediction, and independent preclinical validation would be required before any further clinical consideration.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
Methylphenidate has no products registered with CDSCO in India based on currently available regulatory data (0 licences on file).
Safety Considerations
Drug Interactions: Methylphenidate has 137 documented interactions in the DDInter database. Highest-priority interactions are summarised below:
| Severity | Interacting Drug | Clinical Note |
|---|---|---|
| Major | Bupropion | Increased seizure risk; potential cardiovascular effects |
| Moderate | Isometheptene | Additive sympathomimetic vasoconstriction |
| Moderate | Ephedrine | Additive sympathomimetic effects, blood pressure elevation |
| Moderate | Epinephrine | Additive cardiovascular stimulation |
| Moderate | Polyethylene glycol (3350 with electrolytes) | Potential interaction |
| Moderate | Picosulfuric acid | Potential interaction |
| Moderate | Sodium sulfate | Potential interaction |
| Unknown | Metformin, Morphine, Omeprazole, Pantoprazole, Simvastatin, Prednisone, Vancomycin, and others | Clinical significance not fully characterised |
Please refer to the package insert for complete warnings and contraindications, which were not available in this evidence pack.
Conclusion and Next Steps
Decision: Hold
Rationale: Despite a near-maximum TxGNN prediction score, there is no clinical trial evidence, no supporting literature, and no established mechanistic link between Methylphenidate’s catecholamine reuptake inhibition and the FGD1/Rho GTPase pathway defect that drives faciodigitogenital syndrome. The high score is best explained by phenotypic co-occurrence patterns in the knowledge graph, not pharmacological plausibility.
To proceed, the following would be needed:
- Preclinical studies (cell model or animal model) demonstrating a functional interaction between catecholamine signalling and FGD1/Rho GTPase pathway activity
- Systematic review of cognitive and behavioural phenotypes in faciodigitogenital syndrome to assess whether dopaminergic dysregulation is a documented feature
- India CDSCO regulatory filing and package insert data (warnings, contraindications) to complete the safety profile
- DrugBank MOA data retrieval (DG002) to enable formal mechanistic-link analysis
- Clinical case series or registry data documenting stimulant medication use in Aarskog-Scott syndrome patients, if any exist
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.